Skip to main content

Table 1 Characteristics of male BRCAm carriers with a diagnosis of tumor in SYSUCC cohort

From: Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey

Variables

Male BRCAm carriers (n = 52)

Age at diagnosis (y)

 < 40

4(7.7)

 40–49

3(5.8)

 50–59

15(28.8)

 60–69

21(40.4)

 70–79

8(15.4)

 ≥ 80

1(1.9)

Family history of tumor

 no

35(67.3)

 yes

15(28.8)

 unknown

2(3.8)

Diagnose of multiple tumors

 no

48(92.3)

 yes

2(3.8)

 unknown

2(3.8)

Anatomic site of tumor

 prostate

19(36.5)

 colon/rectum

13(25.0)

 stomach

7(13.5)

 lung

4(7.7)

 kidney

2(3.8)

 head and neck

2(3.8)

 breast

1(1.9)

 bladder

1(1.9)

 other

3(5.8)

Histology

 adenocarcinoma

38(73.1)

 mucinous adenocarcinoma

3(5.8)

 urothelial carcinoma

3(5.8)

 squamous cell carcinoma

2(3.8)

 undifferentiated carcinoma

2(3.8)

 neuroendocrine carcinoma

2(3.8)

 other

3(5.8)

TNM stage

 I

1(1.9)

 II

6(11.5)

 III

15(28.8)

 IV

28(53.8)

 unknown

2(3.8)

BRCA1/2 mutation

 BRCA1 only

16(30.8)

 germline

3(5.8)

 somatic

13(25.0)

 both germline and somatic

0(0.0)

 BRCA2 only

33(63.5)

 germline

4(7.8)

 somatic

26 (50.0)

 both germline and somatic

3(5.7)

 both BRCA1 and BRCA2

3(5.8)a

MSI

 MSS

26 (50.0)

 MSI-H

7(13.5)

 unknown

19(36.5)

TMB

 low (< 10 muts/Mb)

17 (32.7)

 moderate (10–20 muts/Mb)

2(3.8)

 high (> 20 muts/Mb)

14 (26.9)

 unknown

19(36.5)

Surgery

 no

17 (32.7)

 yes

34 (65.4)

 unknown

1(1.9)

Endocrinotherapy

 no

40 (76.9)

 yes

11 (21.2)

 unknown

1(1.9)

Chemotherapy

 no

16(30.8)

 yes

35(67.3)

 unknown

1(1.9)

Radiotherapy

 no

36 (69.2)

 yes

15(28.8)

 unknown

1(1.9)

Immunotherapy

 no

44 (84.6)

 yes

7(13.5)

 unknown

1(1.9)

Targeted therapy

 no

47 (90.4)

 yes

4(7.7)

 unknown

1(1.9)

Tumor progression

 no

29 (55.8)

 yes

22 (42.3)

 unknown

1(1.9)

Survival

 alive

41 (78.9)

 deceased

10 (19.2)

 unknown

1(1.9)

  1. aSomatic mutation in both BRCA1 and BRCA2 is found in three cases
  2. BRCA Breast cancer susceptibility gene, MSI Microsatellite instability, MSS Microsatellite stable, MSI-H Microsatellite instability-high, TMB Tumor mutational burden